NL-OMON49226招募中4 期
The effect of twice daily aclidinium bromide/formoterol fumarate 340/12 mcg vs. once daily tiotropium 'respimat' 5mcg on static and dynamic hyperinflation in patients with COPD during 24 hours. - BOTH study (BrOchodilaTion Hyperinflation)
CIRO+, expertisecentrum voor chronisch orgaanfalen0 个研究点目标入组 49 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 49
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Patients with COPD with static hyperinflation above the higher limit of normal
- •defined as 1,64 times the standard deviation above the predicted value.
排除标准
- •Patients treated with oral corticosteroids and/or antibiotics for an
- •exacerbation and/or lower respiratory tract infection in the 4 weeks prior to
- •Patients with hypercapnia (>= 6.5 kPa).
- •Patients unable to perform bodybox measurements
- •Known respiratory disorders other than COPD which may impact the efficacy of
- •the study drug.
- •Patients with clinically significant cardiovascular conditions.
研究者
相似试验
进行中（未招募）
1 期
The effect of dual bronchodilation versus single bronchodilation on 24-hour hyperinflation in COPD patientsEUCTR2016-003989-12-NLCIRO, center of expertise in chronic organ failure
已完成
3 期
Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo when administered to patients with stable chronic obstructive pulmonary disease (COPD).COPDprogressive respiratory disease10006436NL-OMON38263Almirall44
已完成
不适用
Efficacy and Safety of Aclidinium Bromide at Two Dose Levels vs Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)-J449 Chronic obstructive pulmonary disease, unspecifiedChronic obstructive pulmonary disease, unspecifiedJ449PER-107-09aboratorios Almirall, S.A.,
进行中（未招募）
1 期
Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD)Moderate to severe chronic obstructive pulmonary disease (COPD)MedDRA version: 9.1Level: LLTClassification code 10009033Term: Chronic obstructive pulmonary diseaseEUCTR2009-011600-27-FRaboratorios Almirall, S.A.
进行中（未招募）
不适用
Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD)EUCTR2009-011600-27-DEaboratorios Almirall, S.A.810